LONDON, Dec 9 (Reuters) - Swiss drugmaker Roche (ROG.VX) is advancing two experimental drugs for schizophrenia and multiple sclerosis into late-stage clinical trials, as it diversifies from a traditional reliance on cancer treatments.
LONDON, Dec 9 (Reuters) - Swiss drugmaker Roche (ROG.VX) is advancing two experimental drugs for schizophrenia and multiple sclerosis into late-stage clinical trials, as it diversifies from a traditional reliance on cancer treatments.
